The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.
Yazarlar (33)
Mersin Üniversitesi, Türkiye
Türkiye
Prof. Dr. Ayşe KEFELİ
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Türkiye
Türkiye
Türkiye
İzmir Katip Çelebi Üniversitesi, Türkiye
Mersin Üniversitesi, Türkiye
Hatay Mustafa Kemal Üniversitesi, Türkiye
T.C. Sağlık Bakanlığı, Türkiye
Türkiye
Ege Üniversitesi, Türkiye
Türkiye
Türkiye
T.C. Sağlık Bakanlığı, Türkiye
Türkiye
T.C. Sağlık Bakanlığı, Türkiye
Dokuz Eylül Üniversitesi, Türkiye
Türkiye
Türkiye
Marmara Üniversitesi, Türkiye
Koç Üniversitesi, Türkiye
Türkiye
Karadeniz Teknik Üniversitesi, Türkiye
Türkiye
Türkiye
Türkiye
Ondokuz Mayıs Üniversitesi, Türkiye
Dokuz Eylül Üniversitesi, Türkiye
Türkiye
Türkiye
T.C. Sağlık Bakanlığı, Türkiye
Ege Üniversitesi, Türkiye
| Makale Türü | Özgün Makale |
| Makale Alt Türü | ESCI dergilerinde yayınlanan tam makale |
| Dergi Adı | Hepatology forum |
| Dergi ISSN | 1307-5888 Wos Dergi Scopus Dergi |
| Dergi Tarandığı Indeksler | ESCI |
| Makale Dili | İngilizce |
| Basım Tarihi | 09-2023 |
| Cilt No | 4 |
| Sayı | 3 |
| Sayfalar | 92 / 96 |
| DOI Numarası | 10.14744/hf.2023.2023.0001 |
| Makale Linki | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564251/pdf/hf-4-092.pdf |
| Özet |
| Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC. |
| Anahtar Kelimeler |
| Chronic hepatitis C | real-life experience | glecaprevir-pibrentasvir |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları |